Ethnic minorities in England less likely to get breast cancer diagnosis from routine screening

Ethnic minority women in England receive breast cancer diagnoses through routine screening at rates up to one-third lower than their white counterparts, according to research from the University of Surrey funded by Breast Cancer Now.

Instead, people from minority ethnic backgrounds face higher odds of diagnosis in emergency settings or through urgent referral pathways. The finding emerges from analysis of 86,564 adults diagnosed with breast cancer between 2009 and 2019, drawn from two large datasets: the Clinical Practice Research Datalink and the Cancer Registration Tumour and Treatment datasets.

The research suggests a disparity in screening access or uptake among England's ethnic minority populations. Routine mammographic screening typically identifies cancers at earlier stages when treatment options are broader and outcomes tend to be better. Emergency diagnoses often signal disease detected at more advanced stages, when symptoms prompt hospital admission rather than preventive screening.

The University of Surrey study does not specify which ethnic minority groups face the steepest disparities, nor does it isolate the causes. The source material does not address whether barriers stem from awareness gaps, language obstacles, cultural factors, geographic access to screening clinics, or systemic factors within the healthcare system.

Breast Cancer Now, the charity backing the research, has long flagged inequalities in cancer diagnosis and treatment across demographic groups in the UK. The exclusive analysis adds quantitative evidence to that advocacy, showing the disparity persists across a full decade of recent data.

The findings carry implications for health policy in England. If minority ethnic women are systematically underrepresented in routine screening programmes, targeted outreach, culturally sensitive communication, and removal of structural barriers may be needed to close the gap. Earlier detection through screening typically improves survival rates and reduces the need for more intensive treatments.

The research does not indicate whether the disparity has widened, narrowed or remained stable over the study period, nor does it provide comparative data from other nations with similar screening programmes.